2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. (September 2015) - Lin, K.; Sun, J.; Maloney, L.; Goble, S.; Oza, A.; Coleman, R.; Scott, C.; Robillard, L.; Mann, E.; Isaacson, J.; Harding, T.; Giordano, H.; et al.